

## Certification Form for Human Pluripotent Stem Cell Line Derivation

Title 17 California Code of Regulations Section 100080(f) designates all human pluripotent stem cell lines derived in accordance with the CIRM regulations as "acceptably derived." Derived cell lines may be used in CIRM funded research. Lines derived in accordance with the CIRM regulations conform to the 2008 Amendments to the National Academies' Guidelines for Human Embryonic Stem Cell Research.

This form is designed for researchers or institutions seeking designation of a human pluripotent stem cell line as "acceptably derived." The information provided herein will be utilized to support the registration and designation of human pluripotent stem cell lines as "acceptably derived."

- ❖ Part A is to be completed by the SCRO committee or equivalent.
- ❖ Part B may be completed by a SCRO committee, researcher or other institutional official.

## Part A: To be completed by the SCRO committee or equivalent.

SECTION I – Research Oversight Committee				
Oversight committee name		Committee contact / Institutional official		
University of California, San Francisco - Gamete Embryo and Stem Cell Research Committee (GESCR)		Bernard Lo, M.D GESCR Committee Chair		
Street address	Street address		City & State	
512 Parnassus Ave., Room C-126, Box 0903			San Francisco, CA	
ZIP / Post code	Daytime telephone		e-mail address	
94143-0903	415-476-5370		bernie@medicine@ucsf.edu	
Is this committee constituted in a manner consistent with California Code of Regulations Section 100060?   ☐ Yes ☐ No				
SECTION II – Derived Cell Line Information				
The oversight committee identified in Section I reviewed and approved the protocol for derivation of the human pluripotent stem cell line identified in this section.				
Institution or Entity Deriving Cell Line		Principal Investigator		
University of California, San Francisco		Susan Fisher, Ph.D.		
Name or Designation of Cell Line		CIRM Grant Number		
UCSF4 RL		RL1-00648-1		

SECTION III – Donor Consent Information				
Does the approved protocol require <u>each donor</u> of human gametes or somatic cells, used to create the cell line identified in Section II, to provide informed consent for the <u>research use</u> of their biological material for cell line derivation?	⊠Yes □No			
Was the original procurement protocol for obtaining gametes, blastocysts or somatic cells from human subjects approved by an IRB, as described in federal regulations at 45 CFR 46.107, (or a foreign equivalent)?	⊠Yes □No			
Was the consent protocol for obtaining gametes, blastocysts or somatic cells from human subjects consistent with California Code of Regulation section 100100?	⊠Yes □No			
Is the consent form available?	⊠Yes □No			
Additional comments or information regarding human subjects status or donor con	nsent:			
See Section VII below.				

SECTION IV – Donor Payments						
The approved protocol for derivation of the human pluripotent stem cell line identified in Section II specified the following payments or reimbursements may be provided to donors.						
×	Original donors of gametes, blastocysts or somatic cells received <u>no payments</u> , cash or in kind.					
	Original donors received reimbursements and/or payments. Indicate type in section below.					
		Derivation source	Donor was reimbursed for direct "permissible expenses <sup>1</sup> "	Donor received payments in excess of direct expenses		
		For surplus IVF- or PGD-blastocyst made for reproductive purposes	☐ Oocyte donor☐ Sperm donor	☐ Oocyte donor ☐ Sperm donor		
		For blastocyst made specifically for research using IVF	☐ Oocyte donor ☐ Sperm donor	Gamete donor may not receive payments		
		For somatic cell nuclear transfer (SCNT) into human oocytes	☐ Oocyte donor ☐ Somatic cell donor	Gamete donor may not receive payments		
		Parthenogenesis using human oocytes	☐ Oocyte donor	Gamete donor may not receive payments		
		Somatic cell reprogramming (iPS)	☐Somatic cell donor	Somatic cell donor may not receive payments		
		Other (describe)				
	Payment status for gamete, embryo or somatic cell donation could not be determined.					
SE	CTIO	N V – Certification For Part A				
	I certify that the statements herein are true and complete to the best of my knowledge.					
	Name Title					
	Berr	nard Lo, M.D.		Professor, Department of Medicine Chair, Gamete, Embryo and Stem Cell Research Committee		
	Signature Date		Date			

<sup>&</sup>lt;sup>1</sup> Direct "permissible expenses" may include, but are not limited to, costs associated with travel, housing, childcare, medical care, health insurance and actual lost wages. See Title 17 California Code of Regulations section 100020(h).

Part B to be completed by a SCRO committee, researcher or other institutional official.

SECTION VI – Derivation Source and Date of Derivation				
Dori	Month and year of:			
Derivation source		blastocyst	consent for	cell line derivation
1	Sumply N/E or DCD blocks syst	formation	research donation	
	Surplus IVF- or PGD-blastocyst made for reproductive purposes <sup>2</sup>	REDACTED ON FILE	REDACTED ON FILE	4/09
	Blastocyst made specifically for			
	research using IVF			
	Somatic cell nuclear transfer			
	(SCNT) into oocytes			
	Parthenogenesis			
	Somatic cell reprogramming (iPS)			
	Other (describe)			
SEC	TION VII – Verification of Donor (	Consent		
Confirm donor consent for applicable source of human pluripotent cells.				
(1)	For any blastocyst created using IVF.			
	☑ Consent for research use provided by all gamete donors			
	☐ Consent for research use provided by oocyte donor only			
	☐ Consent status for gamete donor(s) unknown			
	Other (describe):			
(2)	2) For SCNT or parthenogenesis.			
	☐ Consent for research provided by all gamete and somatic cell donors.			
	☐ Other (describe): No consent for SCNT orparthenogenesis			
(3)	(3) For Somatic cell reprogramming (iPS)			
	Consent for research provided by all somatic cell donors			
	Other (describe): No consent for somatic cell reprogramming (iPS)			

<sup>&</sup>lt;sup>2</sup> The purpose of blastocyst formation was for reproductive use. The individual(s) with custody of the embryo determined it was no longer required for reproductive use.

SECTION VIII – Link to Donor, Medical History & Restrictions				
Is/are the donor(s) gametes or somatic cells iden between the donor(s) and the derived human plu		⊠Yes □No		
Is there a donor medical history associated with t	⊠Yes □No			
Did the donor(s) consent to being contacted?		⊠Yes □No		
Are there any restrictions or limitations on the use	⊠Yes □No			
If yes, describe any restriction or limitations on th	e use of derived lines.			
An identifiable link exists between the IVF Tissue Bank and the donors, but the embryos were de-identified before being given to Dr. Fisher.  No SCNT permitted.				
SECTION IX – Certification For Part B				
By signing this document I certify that this cell line was derived in a manner consistent with the protocol described in Part A, and the statements herein are true and complete to the best of my knowledge.				
Name	Title			
Elena Gates, M.D.  Professor, Department of OB/GYN & Repro.Sci				
Susan Fisher, Ph.D.  Director, UCSF IVF Tissue Bank  Professor, Department of OR/GYN & ReproSc		Repro Sc ±		
Signature	Date			
Addition Information				